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a  b  s  t  r  a  c  t
A blinded,  randomized,  controlled,  multi-centric  ﬁeld  study  was  conducted  on  French  dairy
farms (n  =  9)  to evaluate  the  long  term  efﬁcacy  of metaphylactic,  single  oral  treatments  with
either 1  mg/kg  body  weight  (BW)  of diclazuril  (Vecoxan®),  or 15 mg/kg  BW  of  toltrazuril
(Baycox®) against  natural  infections  with  Eimeria  zuernii  and/or  Eimeria  bovis,  compared  to
untreated  control  animals.  A  total  of 199  calves  from  nine  commercial  farms  aged  between
21 and  55  days  old  at the  start  of  study  were  included  and  randomly  allocated  to one  of  three
groups.  Calves  on all farms  were  observed  for a period  of  78 days  post treatment,  using  both
parasitological  (oocyst  excretion),  and  clinical  parameters  (faecal  score  and  body  weight).
The assessment  of  efﬁcacy  was  based  on both  control  of oocyst  excretion,  and on the average
daily  weight  gains  throughout  the  study.
During the  whole  study  period,  the  mean  number  of days  with  diarrhoea  (≥2)  was  simi-
lar  (0.7  days)  between  treated  groups.  Excretion  in the  untreated  group  peaked  at  21 days
after treatment.  In both  the diclazuril  and  toltrazuril-treated  groups,  mean  oocyst  excre-
tion decreased  dramatically  in the  ﬁve  days  following  treatment.  Thereafter,  particularly
towards  the  end  of  the study  period,  oocyst  counts  and  percentage  levels  of  E. zuernii  were
highest  in  the  toltrazuril-treated  group.  In  pooled  data  from  all  trial  sites,  the  average  daily
weight gain  was  signiﬁcantly  (p = 0.01)  higher  (+0.057  kg/day)  in  the  diclazuril  group  when
compared  to the toltrazuril  group,  and  the  average  body  weight  gain  of the  diclazuril  treated
group  was 4.4  kg higher  than  the  toltrazuril  group.  On  eight  of  the  nine  trial sites,  the  aver-
age daily  gain  was greater  in  the  diclazuril  group  than  in  the  toltrazuril  group.  This study
demonstrates  that,  over  an  extended  observation  period  of  78  days,  metaphylactic  treat-
ment with  both  diclazuril  and  toltrazuril  reduces  the  impact  of  coccidiosis,  but  greater
performance  beneﬁts  based  on  average  daily  weight  gains,  were  achieved  following  the
use of  diclazuril.
©  2014  The  Authors.  Published  by  Elsevier  B.V.  This  is an  open  access  article  under  the  CC
Y-NC-NB∗ Corresponding author. Tel.: +33 674915726.
E-mail address: philippe pierre@elanco.com (P. Philippe).
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304-4017/© 2014 The Authors. Published by Elsevier B.V. This is an open acce
icenses/by-nc-nd/3.0/).D  license  (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. IntroductionHistorically, bovine coccidiosis was considered to be a
severe infection only during the calf weaning period and
for a few weeks thereafter. In the weeks prior to weaning,
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rotavirus, coronavirus, Escherichia coli and other pathogens
were considered to be the most common causes of diar-
rhoea and few considered coccidiosis as a severe concern
for calves younger than 1 month of age. More recently,
several surveys have shown that very young calves (from
birth to 3 months old) were infected by Eimeria bovis
and Eimeria zuernii,  the most pathogenic coccidia of cattle
(Daugshies and Najdrowski, 2005), and that poor hygiene,
overcrowding and stressful situations (transport, weaning
etc.) increases the risk of contracting coccidiosis.
During the days following birth, calves can be infected
with Cryptosporidium parvum and sometimes, during the
ﬁrst week of life, by Giardia intestinalis and Strongyloides
papillosus. By the end of the ﬁrst month, coccidia are preva-
lent and numerous oocysts are expelled in the faeces and
recycle quickly (Alzieu et al., 2012). Maximum intensity of
coccidiosis occurs between week 4 and week 7 after birth
(Jäger et al., 2005; Sánchez et al., 2008).
Several recent papers have stressed that bovine coc-
cidiosis is a global problem, spreading infection equally
in dairy and beef calves. Intestinal damage is common
with subsequent symptoms of decreased weight gain,
weakness and secondary bacterial infection frequently
reported (Daugshies and Najdrowski, 2005; von Samson-
Himmelstjerna et al., 2006; Bangoura and Daugschies,
2007).
Coccidiosis is generally diagnosed by faecal exam-
ination in order to detect oocysts and it is greatly
recommended that the pathogenic species are identiﬁed if
present. For reporting purposes, most parasitologists con-
sider the presence of E. zuernii and/or E. bovis oocysts
to be more important than their numbers (Jolley and
Bardsley, 2006); as there is no strong correlation between
the numbers of oocysts shed and severity of clinical signs
(Daugschies et al., 2007).
Practitioners must distinguish between viral, bacterial
and parasitic agents involved in the development of gut
diseases of very young calves (Dorchies et al., 2012). Hae-
morrhagic diarrhoea in coccidiosis is not very common but
mild infection by the most pathogenic coccidia, E. zuernii
and E. bovis, impairs nutrient absorption and causes dra-
matic changes in the villous architecture with a reduction
in epithelial cell height and a decrease in extent of the
brush border (Mundt et al., 2005). These lesions result in a
reduction in surface area available for absorption and con-
sequently a decreased feed efﬁciency (Taylor et al., 2007).
Infected animals develop an effective protective immu-
nity to homologous re-infection (Sühwold et al., 2010).
Increased levels of interferon-gamma in primary infection,
appears to be a key feature of coccidiosis control (Taubert
et al., 2008).
The economic consequences of coccidiosis of calves
must be controlled. Unfortunately, it is too late to intervene
after the appearance of ﬁrst clinical signs as signiﬁcant tis-
sue damage has already occurred. Timing of treatment with
respect to the impact on growth is therefore critical. As
well as this, infected animals spread millions of oocysts and
heavily contaminate their environment, spreading infec-
tion to younger calves.
Anticoccidial products are often used for controlling
coccidiosis in calves. However, only a few drugs (theology 206 (2014) 129–137
benzene acetonitriles – diclazuril, toltrazuril) have great
efﬁcacy against pre-existing infection with pathogenic
Eimeria spp. The desired scenario would be to kill the para-
site but also to allow the development of natural immunity
(Agneessens et al., 2006; Taylor et al., 2011). Several stud-
ies have conﬁrmed the efﬁcacy of these drugs on bovine
coccidiosis by trials using either diclazuril (Daugshies and
Najdrowski, 2005; Daugschies et al., 2007; Romero et al.,
2013), or toltrazuril (Bohrmann, 1991; Mundt et al., 2003;
Epe et al., 2005; Mundt et al., 2005); or comparing both
(Mundt et al., 2007; Veronesi et al., 2011). In all but one
study (Veronesi et al., 2011), the monitored periods were
comparatively short, typically less than 56 days.
The aim of the present study was to investigate the
effectiveness of metaphylactic treatments with diclazuril
(Vecoxan®) and toltrazuril (Baycox bovis®) against natural
infections with E. zuernii and/or E. bovis in dairy calves over
a longer (78 day) period.
2. Materials and methods
2.1. Study design
Between August 2010 and March 2012, nine commer-
cial dairy farms in Brittany, France were selected based
on their previous history of coccidiosis outbreaks. More
detailed investigations were then conducted as blind, ran-
domized, controlled, ﬁeld trials in accordance with “Good
Clinical Practice” (VICH guideline GL9) and national animal
welfare requirements.
On each trial site, three groups of calves were randomly
assigned to three different preventive treatments for coc-
cidiosis, in separate pens (Table 1):
◦ Group A: diclazuril treated once 1 mg/kg body weight
(Vecoxan® 0.25% suspension, Elanco Animal Health)
◦ Group B: toltrazuril treated once with 15 mg/kg body
weight (Baycox bovis® 5% suspension, Bayer Animal
Health)
◦ Group C: untreated controls.
Calves in Groups A and B were treated close to the time
of expected observation of clinical coccidiosis, usually 2
weeks after the grouping of animals in collective pens,
where coccidiosis is endemic. Treatments were given on
study day 1 (SD1), i.e. 15 days after grouping in collective
pens.
2.2. Animals
A total of one hundred and ninety nine healthy calves
(Primarily Holstein and Montbeliard) from the Brittany
area (France) were randomly selected from nine dairy
farms (7–45 calves per farm). Twenty two  sequences were
conducted in total. Between 7 and 15 calves were included
in each sequence, and these were divided into three groups
(A, B and C) containing the same numbers of treated ani-
mals, with one untreated calf as a sentinel control in the
ratio 3:3:1; or 4:4:1; or 7:7:1 depending on the number of
calves per farm.
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Table  1
Study design.
Group Treatment Date of treatment Number of calves
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OA Diclazuril 1 mg/kg once per os 
B  Toltrazuril 15 mg/kg once per os 
C  Control Untreated 
Before the inclusion into a sequence, calves were housed
n individual pens. Two weeks before treatment, they were
oved to collective pens. On study day 1 (SD1), calves in
ach treatment group were randomly selected according to
he criteria of age, sex, body weight and breed. From SD1 to
he end of study, the calves were housed in collective pens,
eparated according to treatment groups. All calves were
ndividually monitored from SD1 until SD78 (i.e. the end of
he trial).
None of the calves had received anti-coccidial treatment
rior to the beginning of the trial.
At the beginning of the study (SD1), diclazuril and
oltrazuril-treated groups (A and B) were not statisti-
ally different with regards to age, oocyst excretion, body
eight, sex or faecal score (p > 0.05) (Table 2).
.3. Parameters
.3.1. Clinical examination
All calves were submitted to three complete health
hecks with individual weights recorded on SD1, SD22 and
D78. Individual body weights were quantiﬁed by weigh-
ng the calves on a weighing scale, calibrated at each use.
.3.2. Faecal examination, oocyst counts and
dentiﬁcation
From SD1 to SD78, individual rectal faeces samples were
aken twice weekly, and faecal consistency was evaluated
mmediately on site, according to a faecal score (FS) using
 scoring system (0 = No diarrhoea, normal faeces; 1 = Pasty
aeces to semi-liquid; 2 = Watery faeces; 3 = Watery fae-
es with blood; 4 = Watery faeces with blood and tissues).
iarrhoea was present when FS was ≥2.
Oocyst counts were performed using a modiﬁed
cMaster method, mixing 3 g of faeces per 42 ml  of
aturated NaCl solution (speciﬁc gravity = 1.20). The fae-
al oocyst counts were evaluated and species identiﬁed
irectly, according to the size and the shape of non-
porulated oocysts (Taylor et al., 2007).
For pathogenic coccidia, E. bovis and E. zuernii,  faecal
xcretion of 500 opg or more is usually accepted as the
able 2
bservational ﬁndings for treatment groups at the start of the trials (SD1).
Variable Group 
Percentage of calves excreting Eimeria spp oocysts 42 
Percentage of calves with Eimeria spp opg > 500 23.8 
Percentage of calves with E. zuernii and E. bovis opg > 500 15.9 
% of calves with faecal score ≥2 11.3 
Body weight (kg) (mean ± standard deviation) 60.4 ± 
Age at treatment (days) (mean ± standard deviation) 41.35 ±
Sex F: 51 M
a Mann–Whitney test.
b Fisher test.SD1 88 (51 females, 37 males)
SD1 88 (52 females, 36 males)
- 23 (14 females, 9 males)
threshold indicating coccidia-induced diarrhoea (Mundt
et al., 2005).
2.4. Statistical methods
Data collected at the individual trial sites were
pooled and analyzed descriptively and statistically. Non-
parametric statistical tests were used to perform compar-
isons between groups.
All qualitative data (qualitative oocyst excretion, inci-
dence and prevalence of diarrhoea) were tested with
Fisher’s exact test. The quantitative data (quantitative
oocyst excretion, body weight, age) were tested with the
Mann–Whitney test.
Growth performance was  analyzed by calculating
weight gain between the end of the study period (SD78)
and the day of treatment (SD1). A multiple linear regres-
sion model with mixed effect was  used to compare average
daily gain between groups.
Effects were considered signiﬁcant at an error level of
5% (p = 0.05) or lower.
3. Results
3.1. Parasitological data
In all of the trial sites, all control calves expelled
oocysts at each faecal examination. Highest mean counts
in this group were observed between SD12 to SD26
(Fig. 1), and then decreased. Oocyst differentiation of
samples taken from the control calves indicated that E.
bovis predominated during the initial period but then
declined. The pattern of E. zuernii oocyst excretion fol-
lowed that of E. bovis, but ﬂuctuated in higher numbers
and percentage presence throughout the study period
(Figs. 1 and 2). Oocyst excretion for other (non-pathogenic)
Eimeria species also ﬂuctuated throughout, suggesting that
there was  exposure to several different species over time.
Total oocyst, E. bovis and E. zuernii output for the two
treatment groups are also given in Figs. 1 and 2, with the
of Eimeria species present shown in Fig. 2. The percentages
A: Diclazuril Group B: Toltrazuril p-value
45.4 0.38b
27.3 0.36b
17 0.5b
6.8 0.22b
10.3 59.9 ± 9 0.92a
 13.56 41.01 ± 13.76 0.36a
:  37 F: 52 M:  36 0.5b
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Fig. 1. Mean log (OPG + 1) of total oocysts; E. bovis oocysts; and E zuernii oocysts per gram of faeces for control, diclazuril and toltrazuril-treated groups
over  the study period (SD1-SD78).
Fig. 2. Percentage numbers of oocysts of E. bovis; E. zuernii,  and other Eimeria spp. in controls; diclazuril; and toltrazuril-treated groups over the study
period  (SD1-SD78).
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Fig. 3. Percentage of calves with oocy
f calves excreting oocysts of the two pathogenic coccidia
pecies (E. zuernii and E. bovis > 500 opg) in both treatment
nd control groups, are given in Fig. 3.
Although it was apparent that less than 20% of treated
alves were infected on SD1, the numbers of calves
xcreting oocysts in the two treated groups dramatically
ecreased in the ﬁve days following treatment. From SD12
o SD33, the percentage of calves excreting oocysts in group
 (toltrazuril), was signiﬁcantly (p < 0.05) lower than for
alves in group A (diclazuril). From SD36 to SD78, less dif-
erences were observed, except for SD54, SD57, SD64 and
D68 when the percentage of calves in group A (diclazuril)
xcreting oocysts were signiﬁcantly (p < 0.05) lower than
or group B calves (toltrazuril). Two months after treat-
ent (SD57), almost 40% of toltrazuril-treated calves were
hedding oocysts of the pathogenic coccidia species (E.
uernii + E. bovis > 500 opg), the largest proportion of which
ere E. zuernii (Figs. 1–3).
During the entire study period, the mean number of
ays with diarrhoea (faecal score ≥2.0) in the treated
roups was low (<10%). There was similarity (0.7 days,
 = 0.64) shown between treated groups but the untreated
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Fig. 4. Percentage of calves showingzuril Control
ts of E. bovis and E. zuernii >500 opg.
controls displayed higher (1.6 days) days of diarrhoea
with a faecal score greater than 2.0. In the diclazuril,
and toltrazuril-treated groups, the percentage of calves
showing diarrhoea decreased from SD1 to SD78 (Fig. 4).
There were no statistical differences between the treat-
ment groups.
3.2. Growth performance
For all trial sites, the average body weight gain of group A
calves (diclazuril) was 4.4 kg higher than the group B calves
(toltrazuril). Using a multiple linear regression model with
mixed effect (data normally distributed, Shapiro–Wilk
normality test, p-value = 0.5379), the diclazuril treated
calves had an average daily gain (ADG) of 0.057 kg/day,
signiﬁcantly (p = 0.01) higher compared to calves in the
toltrazuril group over the 11 weeks post-treatment obser-
vation period. Between SD1 and SD22, the ADG was  not
signiﬁcantly different between the two  treatment groups,
whereas ADG of the group A (diclazuril) calves was higher
(74 g/day) between SD22 and SD78 when compared to the
group B (toltrazuril) calves (Fig. 5).
1 43 47 50 54 57 61 64 68 71 75 78
 Day s
oltrazuril Control
 diarrhoea (faecal score ≥2).
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tal obseFig. 5. Average body weight gain study days SD1-SD22, SD22-SD78 and to
The ADGs differed noticeably between trial sites, which
were most likely due to differing breeds and farm man-
agement practices (Fig. 6). In eight out of nine trial sites,
a higher ADG was recorded for diclazuril-treated calves in
comparison to toltrazuril-treated calves. Statistical analy-
sis was not signiﬁcant at the individual farm level, due to
the limited number of calves included in each trial site.
4. Discussion
Published studies dealing with the control of bovine
coccidiosis conﬁrm that benzene acetonitrile compounds
are effective against various life cycle stages of Eimeria and
consequently, and are well suited for metaphylactic treat-
ment (Bohrmann, 1991).
The timing of treatment is very important, particu-
larly for dairy calves because they typically spend their
ﬁrst 3 or 4 weeks of life in individual pens before being
gathered with other calves into infected yards, often on dif-
ferent premises. At this time, calves are exposed to multiple
stresses and subsequently are prone to bacterial, viral and
Fig. 6. Average daily weight gain rvation period (SD1-SD78) in the diclazuril and toltrazuril-treated groups.
parasitic infections. It is well known that coccidiosis treat-
ment at such a time is only curative and retrospective. By
the time of treatment, it is too late to avoid the development
of extensive intestinal lesions. Consequently, most practi-
tioners will administer metaphylactic treatment between
8 and 15 days after movement of calves on dairy farms. In
this study, the inclusion of sentinel, control calves conﬁrms
a high level of oocyst excretion at SD1, i.e. 15 days after
introduction onto their respective farms, and the presence
of oocyst counts >1000 opg comprising approximately 70%
pathogenic Eimeria species (Fig. 2). These results fully jus-
tify the timing of metaphylactic treatment with one of the
benzene acetonitrile anticoccidial products. Ideally, admin-
istration of these drugs after the ﬁrst infection should
allow the development of immunity protecting against
new severe coccidia infections.
Four main criteria allow the comparison of trial results
of benzene acetonitriles (Bohrmann, 1991; Mundt et al.,
2003, 2005, 2007; Daugshies and Najdrowski, 2005; Epe
et al., 2005; Daugschies et al., 2007; Veronesi et al., 2011;
Romero et al., 2013): (1) the duration of the study, (2)
(kg/day) at each trial site.
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ocyst excretion of pathogenic species, (3) diarrhoea score
nd (4) body weight gain or/and the ADG. Most previ-
us studies have considered that the goal of treatment is
uppression of oocyst excretion, i.e. parasitological crite-
ia, which cannot be evaluated directly in the ﬁeld. In this
tudy, clinical criteria (diarrhoea and growth performance)
ave also been considered as additional useful indicators
or monitoring treatment efﬁcacies.
.1. Study duration
Compared to previous reported studies, this study
rings the results of a longer monitoring period (78 days
ost treatment) along with higher numbers of calves
ncluded in the trial. The mean age of calves at the begin-
ing of the trial was 40 days and at the end of the trial
ver 118 days; i.e. during the period of highest suscepti-
ility to clinical coccidiosis (Taylor and Catchpole, 1994).
his has not been the case in previously described studies
omparing toltrazuril and diclazuril. One study gives a very
hort follow-up period; only 43 days (Mundt et al., 2007);
he other study (Veronesi et al., 2011) had two groups of
alves treated with both drugs, and a non-treated con-
rol group monitored over a period of 40 weeks, but with
o data provided on the kinetics of oocyst excretion. The
esults of this trial cannot therefore be easily compared
ith other, shorter duration trials due to the fact that calves
re reportedly, typically susceptible to clinical coccidiosis
etween 3 weeks to six months in the ﬁeld (Taylor and
atchpole, 1994) and the fact that it is very difﬁcult to
ttribute the effects of a single metaphylactic treatment
0 weeks later.
.2. Oocyst excretion of the pathogenic coccidia E. zuernii
nd E. bovis.
Kinetics of the comparative studies of Mundt et al.
2007) and those of this trial are very different because
f the respective study periods. In this study, oocysts dis-
ppeared from faeces for ﬁve days post-treatment, and
e-appeared more rapidly for the group A (diclazuril) calves
ompared to the group B (toltrazuril) calves. However,
uring the second part of the study (SD36 to SD78), the
evels of oocyst excretion for group B (toltrazuril) calves
hen increased when compared to the group A (diclazuril)
reated calves. During the initial challenge period, the pre-
ominant pathogenic species present was E. bovis, which
hen declined, only to be superseded by E. zuernii.  Levels
f the non-pathogenic Eimeria species ﬂuctuated through-
ut. Towards the end of the study period, however, oocyst
ounts and the percentages of pathogenic species with OPG
500 opg were higher in the toltrazuril-treated group, with
. zuernii predominating. We  summarise that the higher
evels of protection provided immediately post-treatment,
ad prevented the development of species-speciﬁc immu-
ity to E. zuernii in the toltrazuril-treated group leading to
ub-clinical coccidiosis and an impact on growth. Due to
he published persistency of toltrazuril, these observations
re highly unlikely to have been observed in previously
ublished trials of shorter duration.ology 206 (2014) 129–137 135
4.3. Faecal diarrhoea score
Farmers are used to treating calves as soon as diarrhoea
is observed in a group of young calves. Similar to other stud-
ies (Daugshies and Najdrowski, 2005; Mundt et al., 2007),
there was no signiﬁcant correlation shown between diar-
rhoea and oocyst excretion in this trial. The present study
reports a mean duration of diarrhoea of only 0.7 days after
treatment. This result is similar to those reported by Mundt
et al. (2007) in all trial groups without showing any signif-
icant difference.
5. Weight gain
This criterion is one of the most critical from a clini-
cal perspective, allowing an objective evaluation (clinical
criteria) of the consequences of metaphylactic treat-
ment. In this 78-day study, the diclazuril-treated group
(group A) had a mean body weight of 4.4 kg greater
than the toltrazuril-treated group (group B). Unlike the
ﬁndings of Mundt et al. (2007), we  demonstrate that
ADG is signiﬁcantly higher (+0.057 kg/day (p = 0.01)) in
the diclazuril-treated group (group A) compared to the
toltrazuril-treated group (group B). This ﬁnding is most
probably the result of the longer study period; the main
effect of metaphylactic treatment being observed one
month after administration. The most important factor
for farmers is a higher growth rate. Here, it must be
stressed that these results was  observed within the period
of reported highest susceptibility of calves to coccidiosis (3
weeks to 6 months of age) when reared under commercial
farm conditions.
Interestingly, it is possible to differentiate between two
periods in this study:
a) Between SD1 and SD22: despite a higher percentage of
calves excreting oocysts in the diclazuril-treated group
A calves, the ADG and the faecal score were similar
between the two groups.
b) Between SD22 and SD78: when the percentage of calves
excreting oocysts increases in the toltrazuril-treated
group B; and the ADG is higher for the diclazuril-treated
group A calves than for the toltrazuril-treated group B
calves. This latter period comprises the total difference
in ADG between both groups.
It may  appear surprising with particular regard to the
concept of metaphylactic treatment in controlling coccid-
iosis in older calves that the suppression of oocyst excretion
over a longer period of time (in the toltrazuril-treated
calves) does not correlate with higher growth performance
or lower diarrhoea. Epidemiological studies (Jäger et al.,
2005; Sánchez et al., 2008; Alzieu et al., 2012) show that
younger calves are more susceptible to coccidiosis, with a
peak average of excretion prevalence between 30 and 50
days of age. Neonate calves are immunologically naïve at
birth; the development of the immune system in calves
progresses from conception to maturity at approximately
6 months after birth. In order to enhance the adaptive
immune response, newborn calves need to “experience”
pathogens (Chase et al., 2008). Consequently, persistent
y Parasit136 P. Philippe et al. / Veterinar
or longer-acting treatments against coccidiosis in young
calves could delay development of the immune response;
and in this respect the toltrazuril-treated calves in this
study displayed a peak of excretion prevalence 60 days
after treatment, suggesting a detrimental effect on growth
performance. It has previously been surmised that treat-
ments with a benzene acetonitrile compound may  have
an effect on the development of immunity to coccidial
infection in cattle and that if a treatment did interfere
with the acquisition of immunity following subsequent re-
exposure, then severe disease may  follow (Jonsson et al.,
2011). A study conducted by Taylor et al. (2011) with
diclazuril given at 1 mg/kg BW (recommended dose) to
lambs, demonstrated that at this dose level the treatment
was effective in preventing coccidiosis in lambs, but at
higher dose levels (2.0 and 4.0 mg/kg BW)  it appeared to
completely clear the lambs of coccidia rendering them
susceptible to re-infection. Due to differences in pharma-
cokinetic properties between diclazuril and toltrazuril, we
can hypothesize that differences in dose rate (diclazuril
1 mg/kg; toltrazuril 15 mg/kg) and subsequent periods
of activity, could explain why toltrazuril-treated calves
appear to be more susceptible to infection from 30 days
post treatment compared with diclazuril-treated calves, as
demonstrated by the differences in growth performance
and increased levels of oocyst excretion.
6. Conclusion
This study conﬁrms that benzene acetonitrile drugs are
effective at controlling the pathogenic coccidia, E. bovis
and E. zuernii.  The choice of correct timing for the begin-
ning of preventive treatment must be carefully determined
based on history and farm management. For most calves,
cases of coccidiosis typically develop 15 days after stressful
events or movement on, or between farms. Oocyst counts
on their own are insufﬁcient in evaluating the efﬁcacy of
metaphylactic treatments, and speciation should also be
undertaken. In this study, monitoring ADG over a longer
post-treatment period identiﬁed an advantageous effect
for metaphylatic treatment of dairy calves with diclazuril.
The shorter duration of action appeared to allow a better
degree of exposure to sufﬁcient numbers and species of
Eimeria for subsequent species-speciﬁc protective immu-
nity to develop.
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